Green Gobbler 20% Vinegar Weed Killer is a potent, nonselective vinegar-based product. It’s made from ethanol distilled from ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.